Last reviewed · How we verify
Allegra-D
At a glance
| Generic name | Allegra-D |
|---|---|
| Also known as | Loratadine + pseudoephedrine |
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol (PHASE1, PHASE2)
- Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above (PHASE4)
- : Vascular Function in Health and Disease (PHASE1)
- Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers (PHASE1)
- Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout (PHASE4)
- Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout (PHASE4)
- Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease (NA)
- A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allegra-D CI brief — competitive landscape report
- Allegra-D updates RSS · CI watch RSS
- Pfizer portfolio CI